Sanofi sees higher earnings as blockbuster skin drug soars

In 2021, blockbuster eczema treatment Dupixent was the main growth driver for French Sanofi, and the company forecasts a bright 2022 for the drug.


Sanofi forecast double-digit profit growth for 2022 as blockbuster therapy Dupixent extends its reach in the US and Europe.

Earnings per share, excluding some items, are likely to grow by a low double-digit percentage at constant currencies, the Paris-based company said Friday. Fourth-quarter profit by that measure was EUR 1.38 a share, beating the EUR 1.33 average estimate.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs